Digital Therapeutic Against Migraine Closes New Financing Round

December 20, 2021

Berlin, Germany, December 20, 2021 – Berlin Startup Newsenselab is rounding out a year of successes with their most recent financing round. Headlining the list of achievements is “M-sense Migräne”, a digital health application (DiGA) eligible to be reimbursed by statutory health insurances in Germany. With the results of a randomised controlled trial the company is now aiming to prove the effectiveness of the migraine app. With these milestones reached, both existing and new investors participated enthusiastically in the financing round.

2021 has been a year of accomplishment for the Berlin-based startup Newsenselab GmbH. Their migraine app has completed its first year on the preliminary listing in the register of certified digital health apps, overseen by the ​​German Federal Institute for Drugs and Medical Devices (BfArM). The results are more than encouraging: not only is Newsenselab drawing a positive balance, but the startup can observe its impact on the medical treatment of migraines overall.

The digital health app “M-sense Migräne” has helped its users to manage over 100,000 headache attacks throughout the past year. Physicians trust the app’s functions to support them in their treatment of migraine patients and prescribe the digital health app with increasing frequency.

Seeking to fully prove the effectiveness of their digital health app, Newsenselab conducted the digital, decentralised RCT-trial EMMA this year as well. EMMA was the first clinical study on migraine to be conducted exclusively online, and sets the standard for digital clinical trials and digitized recruitment strategies. As of now, EMMA saw its last patient-out on December 6, and an independent scientific institution is now transitioning from the completion of the clinical evaluation to readying the publication of the results, which are to be expected early in 2022.

Newsenselab is thrilled to add to this successful year by announcing the closing of their most recent financing round. The round was led by Berlin’s IBB Ventures, Dutch impact investor Noaber and Munich based MedTech Entrepreneurs with participation of High-Tech Gründerfonds, Eternity.Health and business angel Dr. Klaus Hilleke. Law firm Dentons advised the company.

The M-sense product empowers patients to better manage their migraines and leads to a series of incremental improvements in their quality of life. The team showed resilience while navigating the turbulent developments in the emerging field of prescription digital therapeutics and has managed to set the standard for digital clinical trials. This combination of healthspan improvement and operational excellence is exactly what we’re looking for at Noaber.

Thijs Schaap, investment manager at Noaber

MedTech Entrepreneurs (MTE) are very excited to support Newsenselab on their journey towards improving lives of chronically ill patients starting with 9 million people suffering from migraine every day in Germany. Newsenselab with their strong team and excellent digital technology perfectly strengthens our portfolio.

Dominik Moll, Managing Partner of MTE

Newsenselab is excited to use this latest financing round to expand on its expertise in creating digital medicine for episodic chronic diseases.

We are very happy about the trust and support that our existing and new investors are extending to us. This gives us the chance to develop digital therapeutics for more indications and expand “M-sense Migräne” in Germany and beyond.

Nils Bottler, newly appointed Managing Director of Newsenselab

I was delighted with the addition of Nils to our senior management team and the new push from investors. Newsenselab is now another crucial step closer to our vision of making medicine precise.

Dr. rer. nat. Markus Dahlem, Managing Director of Newsenselab

About Newsenselab GmbH
The Berlin-based health startup Newsenselab GmbH has developed “M-sense Migräne”, the first digital health application (DiGA) for migraine that can be prescribed by physicians in Germany as an “app on prescription” and shows the highest safety standards. The app has been verified by the German Federal Institute for Drugs and Medical Devices (BfArM) and has been reimbursed by all statutory health insurers since mid-December 2020 as part of the Digital Health Care Act (DVG). “M-sense Migräne” combines diverse non-drug therapy methods from clinical practice, based on the guidelines of modern migraine treatment – personalized, motivating and always available. The goal of the DiGA is to provide personalized therapy for attack reduction via analysis of the individual pain pattern. Newsenselab is also conducting research with partners such as Charité Universitätsmedizin Berlin, as well as the University Hospitals of Halle and Rostock in clinical trials to investigate the effectiveness of DiGAs in the treatment of chronic diseases. Initial results from the EMMA migraine study, one of the first clinical trials to take place entirely online, will be published in 2022.
More information: https://www.newsenselab.com

Press Contact
Diana Hagenberg
Tel: +49 (0)30 – 95 99 92 42
E-Mail: diana.hagenberg@newsenselab.com

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3.5 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has also successfully sold interests in more than 150 companies.

Fund Investors in the public-private partnership include the Federal Ministry of Economics and Energy, KfW Capital, the Fraunhofer-Gesellschaft and 32 companies.

Media Contact
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Head of Marketing & Communications
T.: +49 228 – 82300 – 188
s.grueter@htgf.de

Investor Contact
High-Tech Gründerfonds Management GmbH
Tobias Faupel, Prokurist
T.: +49 151 263 24824
t.faupel@htgf.de